Special considerations for evaluating psilocybin-facilitated psychotherapy in vulnerable populations.


Journal

Neuropharmacology
ISSN: 1873-7064
Titre abrégé: Neuropharmacology
Pays: England
ID NLM: 0236217

Informations de publication

Date de publication:
15 08 2022
Historique:
received: 08 03 2022
revised: 25 04 2022
accepted: 09 05 2022
pubmed: 17 5 2022
medline: 15 6 2022
entrez: 16 5 2022
Statut: ppublish

Résumé

Psilocybin-facilitated psychotherapy shows potential transdiagnostic efficacy for a range of mental health conditions. Though vulnerable populations bear disproportionate mental health burden, they have been largely neglected in the clinical psilocybin literature. However, if the field is to best respond to the diverse needs of individuals from vulnerable populations, care must be taken to ensure these individuals are represented in the empirical research. This report calls attention to this concern by detailing the challenges and opportunities associated with evaluating psilocybin-facilitated psychotherapy in vulnerable populations. First, we show how working with vulnerable populations must be considered in the context of an often-problematic past and differential exposure to and experience with classic psychedelics. We then provide actionable recommendations for future research testing psilocybin-facilitated psychotherapy in vulnerable populations, including an emphasis on recruitment strategies, the appropriate communication and assessment of subjective effects, building therapeutic alliance, multicultural competence, and flexible study designs. On these premises we call for future work in this area, underscoring that there is vast room for improvement and expansion in this rapidly advancing field of study.

Identifiants

pubmed: 35577136
pii: S0028-3908(22)00186-1
doi: 10.1016/j.neuropharm.2022.109127
pii:
doi:

Substances chimiques

Hallucinogens 0
Psilocybin 2RV7212BP0

Types de publication

Journal Article Review Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

109127

Informations de copyright

Copyright © 2022 Elsevier Ltd. All rights reserved.

Auteurs

Cynthia E Ortiz (CE)

Department of Health Behavior, School of Public Health, University of Alabama at Birmingham, USA; Department of Psychology, University of Alabama at Birmingham, USA.

Haley Maria Dourron (HM)

Department of Health Behavior, School of Public Health, University of Alabama at Birmingham, USA.

Noah W Sweat (NW)

Department of Health Behavior, School of Public Health, University of Alabama at Birmingham, USA.

Albert Garcia-Romeu (A)

Department of Psychiatry and Behavioral Sciences, Johns Hopkins University School of Medicine, USA.

Sarah MacCarthy (S)

Department of Health Behavior, School of Public Health, University of Alabama at Birmingham, USA.

Brian T Anderson (BT)

Department of Psychiatry and Behavioral Sciences, Zuckerberg San Francisco General Hospital, University of California, San Francisco, USA; UC Berkeley Center for the Science of Psychedelics, University of California, Berkeley, USA.

Peter S Hendricks (PS)

Department of Health Behavior, School of Public Health, University of Alabama at Birmingham, USA. Electronic address: phendricks@uab.du.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH